Literature DB >> 33591005

Impact of Blood Product Transfusions on the Risk of ICU-Acquired Infections in Septic Shock.

Edwige Péju1,2,3,4,5,6,7,8,9, Jean-François Llitjos1,2,3,4,5,6,7,8,9, Julien Charpentier1, Anne François4, Nathalie Marin1, Alain Cariou1,2, Jean-Daniel Chiche1,2,3,4,5,6,7,8,9, Jean-Paul Mira1,2,3,4,5,6,7,8,9, Jérôme Lambert2,5,6, Matthieu Jamme1,2,3,4,5,6,7,8,9, Frédéric Pène1,2,3,4,5,6,7,8,9.   

Abstract

OBJECTIVES: Transfusions of blood products are common in critically ill patients and have a potential for immunomodulation. The aim of this study is to address the impact of transfusion of blood products on the susceptibility to ICU-acquired infections in the high-risk patients with septic shock.
DESIGN: A single-center retrospective study over a 10-year period (2008-2017).
SETTING: A medical ICU of a tertiary-care center. PATIENTS: All consecutive patients diagnosed for septic shock within the first 48 hours of ICU admission were included. Patients who were discharged or died within the first 48 hours were excluded.
INTERVENTIONS: RBC, platelet, and fresh frozen plasma transfusions collected up to 24 hours prior to the onset of ICU-acquired infection.
MEASUREMENTS AND MAIN RESULTS: During the study period, 1,152 patients were admitted for septic shock, with 893 patients remaining alive in the ICU after 48 hours of management. A first episode of ICU-acquired infection occurred in 28.3% of the 48-hour survivors, with a predominance of pulmonary infections (57%). Patients with ICU-acquired infections were more likely to have received RBC, platelet, and fresh frozen plasma transfusions. In a multivariate Cox cause-specific analysis, transfusions of platelets (cause-specific hazard ratio = 1.55 [1.09-2.20]; p = 0.01) and fresh frozen plasma (cause-specific hazard ratio = 1.38 [0.98-1.92]; p = 0.05) were independently associated with the further occurrence of ICU-acquired infections.
CONCLUSIONS: Transfusions of platelets and fresh frozen plasma account for risk factors of ICU-acquired infections in patients recovering from septic shock. The occurrence of ICU-acquired infections should be considered as a relevant endpoint in future studies addressing the indications of transfusions in critically ill patients.
Copyright © 2021 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33591005     DOI: 10.1097/CCM.0000000000004887

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  4 in total

1.  Transfusion-Associated Immunomodulation in Critically Ill Patients: More Than Just Red Cells?

Authors:  Jeffrey Wang; Willard N Applefeld; Janhavi Athale
Journal:  Crit Care Med       Date:  2021-06-01       Impact factor: 9.296

2.  Association of red blood cell and platelet transfusions with persistent inflammation, immunosuppression, and catabolism syndrome in critically ill patients.

Authors:  Ginga Suzuki; Ryo Ichibayashi; Yuka Masuyama; Saki Yamamoto; Hibiki Serizawa; Yoshimi Nakamichi; Masayuki Watanabe; Mitsuru Honda
Journal:  Sci Rep       Date:  2022-01-12       Impact factor: 4.379

3.  Plasma Transfusion in Septic Shock-A Secondary Analysis of a Retrospective Single-Center Cohort.

Authors:  Maximilian Dietrich; Tobias Hölle; Lazar Detelinov Lalev; Martin Loos; Felix Carl Fabian Schmitt; Mascha Onida Fiedler; Thilo Hackert; Daniel Christoph Richter; Markus Alexander Weigand; Dania Fischer
Journal:  J Clin Med       Date:  2022-07-27       Impact factor: 4.964

4.  Platelet transfusions and thrombocytopenia in intensive care units: Protocol for an international inception cohort study (PLOT-ICU).

Authors:  Carl Thomas Anthon; Frédéric Pène; Anders Perner; Elie Azoulay; Kathryn Puxty; Andry Van De Louw; Andreas Barratt-Due; Sanjay Chawla; Pedro Castro; Pedro Povoa; Luis Coelho; Victoria Metaxa; Laveena Munshi; Matthias Kochanek; Tobias Liebregts; Thomas Kander; Johanna Hästbacka; Morten Hylander Møller; Lene Russell
Journal:  Acta Anaesthesiol Scand       Date:  2022-08-23       Impact factor: 2.274

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.